368 results
P
Nanoparticles
I/C
Use of different units (mass per volume, surface area per volume, particles per volume) to measure toxicity, Comparison of toxicity using different units
O
Reduction in heterogeneity in toxicity measurements for certain subgroups of nanoparticles
P
patients with cancer
I/C
estimating cancer-related costs and disability-adjusted life years (DALYs), different methodologies for estimating costs and DALYs
O
average costs of cancer-related DALYs, costs per disease-related DALY, total costs and indirect costs, cost per cancer-related DALY as a percentage of GDP per capita
P
women undergoing assisted reproduction
I/C
progestins, gonadotrophin releasing hormone (GnRH) analogues
O
live birth rate per woman, live birth or ongoing pregnancy per woman and per embryo transfer, ongoing pregnancy, clinical pregnancy, numbers of oocytes and metaphase-two oocytes, duration of stimulation, gonadotrophin consumption, miscarriage, ectopic pregnancy, multiple pregnancy rates
P
children and adolescents with epilepsy
I/C
Perampanel (PER), no intervention
O
reduction in seizure frequency, complete seizure cessation, adverse events
P
offspring, pregnant women
I/C
per- and polyfluoroalkyl substances (PFAS), no exposure, low exposure, high exposure
O
neurobehavioral problems, attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD)
P
adults
I/C
ActiGraph step counting methods, StepWatch
O
steps per day
P
T2DM, obesity
I/C
bariatric surgery, novel glucose-lowering agents, insulin, placebo/usual care, SGLT2i, GLP1RA, DPP4i
O
HbA1c < 7.0 per cent, body weight
P
migraine patients
I/C
vitamin D supplementation, control group
O
headache attacks per month, headache days per month, MIDAS score, attack duration, headache severity
P
patients with moderate to very severe COPD
I/C
triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2 agonist, ICS/LABA dual combinations
O
exacerbation rate per patient per year, changes from baseline in pre-dose trough forced expiratory volume in 1 s (FEV1)
P
97,213 individuals aged 40 years and older
I/C
analysis of multiple studies conducted within the Asian Eye Epidemiology Consortium (AEEC), comparison between urban and rural residents, comparison between South Asia and East Asia
O
prevalence of geographic atrophy (GA) per 1000 persons